Jan G. M. Klijn

Jan G. M. Klijn's AcademicInfluence.com Rankings

Jan G. M. Klijn

Philosophy

#7935

World Rank

#11220

Historical Rank

Logic

#4969

World Rank

#6315

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Jan G. M. Klijn's Degrees

PhD Medicine University of Amsterdam
Doctorate Medicine University of Amsterdam

Why Is Jan G. M. Klijn Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jan G. M. Klijn's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer (2005) (2812)
Genome-wide association study identifies novel breast cancer susceptibility loci (2007) (2351)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial (2002) (1902)
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. (2004) (1645)
Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series (2007) (983)
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. (2001) (940)
Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations (2002) (860)
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. (2007) (814)
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. (2007) (768)
Subtypes of breast cancer show preferential site of relapse. (2008) (731)
Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype (2005) (667)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. (2002) (619)
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. (2007) (547)
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. (2005) (456)
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients (1997) (452)
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. (2000) (420)
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer (2008) (392)
Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics (2008) (390)
Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics (2008) (390)
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. (2006) (369)
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. (2002) (369)
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. (2000) (352)
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. (2005) (345)
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers (2008) (336)
Rapid detection of BRCA1 mutations by the protein truncation test (1995) (334)
Genes associated with breast cancer metastatic to bone. (2006) (331)
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. (2001) (316)
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. (2001) (308)
RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. (2003) (308)
Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers (2004) (287)
Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. (2003) (284)
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines (2010) (271)
Somatostatin receptors in human endocrine tumors. (1987) (269)
Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. (1992) (256)
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. (2007) (233)
ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. (2000) (232)
Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. (1989) (230)
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. (2003) (226)
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). (2002) (218)
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. (1992) (215)
Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients (1999) (213)
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. (1994) (206)
Prediction of relapse and survival in breast cancer patients by pS2 protein status. (1990) (202)
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. (2000) (202)
A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false‐negative mammography (2002) (198)
Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. (1995) (196)
Survival in hereditary breast cancer associated with germline mutations of BRCA2. (1999) (195)
Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers (2008) (190)
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. (1995) (190)
Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. (2006) (189)
Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. (1990) (183)
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers (2005) (183)
High incidence of somatostatin receptors in human meningiomas: biochemical characterization. (1986) (176)
One Year Follow-Up of Women Opting for Presymptomatic Testing for BRCA1 and BRCA2: Emotional Impact of the Test Outcome and Decisions on Risk Management (Surveillance or Prophylactic Surgery) (2002) (176)
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. (2010) (176)
Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response (2008) (174)
Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. (2000) (162)
The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. (1997) (159)
Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. (1995) (157)
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. (1997) (155)
Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic (2007) (151)
Prognostic significance of cathepsins B and L in primary human breast cancer. (1998) (147)
A genome wide linkage search for breast cancer susceptibility genes (2006) (146)
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. (2003) (146)
The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. (1996) (144)
Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer (2000) (144)
Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. (2003) (143)
Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer (2007) (137)
Antiprogestins, a new form of endocrine therapy for human breast cancer. (1989) (137)
Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. (1992) (135)
The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. (2003) (134)
Tumor Tissue Levels of Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Marker in Primary Breast Cancer (2004) (134)
Survival and prognostic factors in BRCA1-associated breast cancer. (2006) (133)
HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. (2007) (131)
Bcar1/p130Cas Protein and Primary Breast Cancer: Prognosis and Response to Tamoxifen Treatment. (2000) (130)
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. (1989) (130)
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. (2005) (127)
The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome. (1980) (118)
Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer (2013) (116)
Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. (1995) (112)
Molecular profiles of progesterone receptor loss in human breast tumors (2009) (108)
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines (2006) (105)
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. (2009) (105)
Insulin‐like growth factor‐1 receptors and insulin‐like growth factor‐1‐like activity in human primary breast cancer (1989) (104)
The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study (2004) (103)
Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. (1998) (103)
Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition (2006) (102)
The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer (1988) (100)
Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer (2008) (100)
DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients (2008) (99)
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2 (2001) (99)
Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. (1988) (99)
Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. (2005) (98)
Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. (1992) (96)
Factors Affecting Sensitivity and Specificity of Screening Mammography and MRI in Women with an Inherited Risk for Breast Cancer (2006) (95)
Effects of progestagens and Org OD14 in in vitro and in vivo tumor models (1994) (95)
Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer. (2008) (95)
Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. (2004) (93)
Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. (1990) (90)
Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study (2007) (88)
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients (2003) (87)
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. (2001) (87)
Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression (2003) (86)
Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases (2007) (85)
How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study (2005) (85)
Stromal influences on breast cancer cell growth. (1992) (84)
Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies (1990) (83)
Hormone secretion in alcohol-induced pseudo-Cushing's syndrome. Differential diagnosis with Cushing disease. (1979) (81)
Hormonal manipulation of cancer : peptides, growth factors, and new (anti)steroidal agents (1987) (81)
Satisfaction with Prophylactic Mastectomy and Breast Reconstruction in Genetically Predisposed Women (2006) (81)
Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. (2003) (80)
Excess Risk for Contralateral Breast Cancer in CHEK2*1100delC Germline Mutation Carriers (2004) (79)
Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined (2012) (79)
Identification of prognostic factors (1994) (78)
BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials (2007) (78)
Copy number alterations that predict metastatic capability of human breast cancer. (2009) (78)
Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1 (2005) (78)
Treatment of metastatic breast cancer patients with different dosages of megestrol acetate; dose relations, metabolic and endocrine effects. (1984) (75)
Hereditary breast cancer growth rates and its impact on screening policy. (2005) (75)
TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients (1996) (74)
Tamoxifen resistance in breast cancer: elucidating mechanisms. (2001) (73)
Multidrug resistance protein in recurrent breast cancer (1997) (73)
Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. (2001) (72)
Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition (2009) (72)
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. (1998) (72)
Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen (2008) (71)
LHRH-agonist treatment in clinical and experimental human breast cancer. (1985) (71)
Effects of the progesterone antagonist RU486 on ovarian activity in the rat. (1987) (69)
Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress. (2007) (68)
The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. (2003) (67)
Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. (1985) (65)
Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. (1994) (65)
THE SENSITIVITY OF GROWTH HORMONE AND PROLACTIN SECRETION TO THE SOMATOSTATIN ANALOGUE SMS 201–995 IN PATIENTS WITH PROLACTINOMAS AND ACROMEGALY (1986) (65)
Cell biological factors associated with the response of breast cancer to systemic treatment. (1993) (65)
The course of distress in women at increased risk of breast and ovarian cancer due to an (identified) genetic susceptibility who opt for prophylactic mastectomy and/or salpingo-oophorectomy. (2007) (65)
Prognostic value of CD44 variant expression in primary breast cancer (1999) (64)
Expression of urokinase‐type plasminogen activator (uPA) and its inhibitor PAI‐1 in benign, borderline, malignant primary and metastatic ovarian tumors (1996) (64)
Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures (1998) (63)
Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer (1990) (63)
Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources (1996) (62)
Receptors for hormones and growth factors and (ONCO)‐gene amplification in human ovarian cancer (1992) (62)
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer (1999) (62)
A Multicenter Study of Cancer Incidence in CHEK2 1100delC Mutation Carriers (2006) (61)
Clinical relevance of biologic factors in male breast cancer (2001) (61)
Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. (2000) (61)
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. (2011) (59)
Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. (1987) (59)
The incidence of complications during pregnancy after treatment of hyperprolactinemia with bromocriptine in patients with radiologically evident pituitary tumors. (1979) (57)
Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer (1998) (57)
A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships (2007) (56)
Experience of parental cancer in childhood is a risk factor for psychological distress during genetic cancer susceptibility testing. (2006) (56)
The Prognostic Value of BCAR1 in Patients with Primary Breast Cancer (2004) (56)
Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. (2006) (55)
MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC) (2001) (54)
Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. (1989) (54)
The common sense model of self‐regulation and psychological adjustment to predictive genetic testing: a prospective study (2007) (53)
Prognostic factors in human primary breast cancer: Comparison of c-myc and HER2/neu amplification (1992) (53)
CHEK2 1100delC and male breast cancer in the Netherlands (2009) (53)
Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. (1987) (52)
Pleiotropic actions of suramin on the proliferation of human breast‐cancer cells in vitro (1992) (51)
Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families (1999) (51)
Urokinase-Type Plasminogen Activator System in Breast Cancer (2004) (51)
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers (2007) (50)
The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly (1982) (49)
Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes (2012) (47)
Oral Contraceptives and the Risk of Breast Cancer in BRCA 1 and BRCA 2 Mutation Carriers (2002) (47)
Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. (1998) (47)
DNA‐synthesis enzyme activity: A biological tool useful for predicting anti‐metabolic drug sensitivity in breast cancer? (1997) (46)
Interrelationships between tumour size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients. (1980) (46)
MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling (2007) (46)
Clinical breast cancer, new developments in selection and endocrine treatment of patients (1992) (46)
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours (2001) (45)
Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer (2010) (45)
Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Node–Negative Breast Cancer Patients (2006) (44)
Prognostic factors for hereditary cancer distress six months after BRCA1/2 or HNPCC genetic susceptibility testing. (2007) (43)
Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients (1999) (43)
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer (1999) (42)
Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer (2006) (42)
Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer (2009) (41)
Are ATM Mutations 7271T→G and IVS10-6T→G Really High-Risk Breast Cancer-Susceptibility Alleles? (2004) (41)
Decreased risk of stroke among 10-year survivors of breast cancer. (2006) (41)
Transforming growth factor beta secretion from primary breast cancer fibroblasts (1995) (41)
Four human breast cancer cell lines with biallelic inactivating α-catenin gene mutations (2010) (40)
Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes (2012) (40)
Maximum Androgen Blockade Using LHRH Agonist Buserelin in Combination with Short-Term (Two Weeks) or Long-Term (Continuous) Cyproterone Acetate Is Not Superior to Standard Androgen Deprivation in the Treatment of Advanced Prostate Cancer (1998) (40)
Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. (1995) (39)
Hormone Therapy and the Risk of Breast Cancer in BRCA 1 Mutation Carriers (2008) (39)
THE IMPORTANCE OF PITUITARY TUMOUR SIZE IN PATIENTS WITH HYPERPROLACTINAEMIA IN RELATION TO HORMONAL VARIABLES AND EXTRASELLAR EXTENSION OF TUMOUR (1980) (39)
Exploring the course of psychological distress around two successive control visits in women at hereditary risk of breast cancer. (2005) (38)
CHEK2 1100delC Is a Susceptibility Allele for HNPCC-Related Colorectal Cancer (2008) (38)
Assessment of the invasive potential of human gynecological tumor cell lines with the in vitro Boyden chamber assay: influences of the ability of cells to migrate through the filter membrane (1997) (38)
Urokinase‐type‐plasminogen‐activator(UPA) production by human breast (myo)fibroblasts in vitro: Influence of transforming growth factor‐β1 (TGFβ1) compared with factor(s) released by human epithelial‐carcinoma cells (1998) (38)
The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for hereditary breast cancer (2004) (37)
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients (2008) (37)
Combined effects of buserelin, estradiol and tamoxifen on the growth of MCF-7 human breast cancer cells in vitro. (1986) (37)
Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient (2006) (37)
The clinical use of somatostatin analogues in the treatment of cancer. (1990) (37)
Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing (2003) (37)
Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases. (1993) (36)
Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. (2007) (36)
Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments (1984) (35)
Association between rb‐1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival (1995) (35)
Prognostic significance of TP53 accumulation in human primary breast cancer: Comparison between a rapid quantitative immunoassay and SSCP analysis (1996) (35)
Family history of breast cancer and local recurrence after breast-conserving therapy. The Dutch Study Group on Local Recurrence after Breast Conservation (BORST). (1998) (34)
Cytokine‐regulated urokinase‐type‐plasminogen‐activator (uPA) production by human breast fibroblasts in vitro (1999) (34)
Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update (2009) (33)
Tamoxifen Resistance in Breast Cancer (2012) (32)
The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. (1983) (32)
Inhibin immunoreactivity in gonadal and non-gonadal tumors (1990) (31)
Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay. (1992) (31)
Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas. (1985) (30)
Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease (2003) (30)
Low-risk susceptibility alleles in 40 human breast cancer cell lines (2009) (30)
Ki‐67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: Correlation with steroid receptors, epidermal‐growth‐factor receptor and cathepsin D (1994) (29)
Androgen Pathway Dysregulation in BRCA1-Mutated Breast Tumors (2003) (29)
Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy (2009) (28)
Early diagnosis of hereditary breast cancer by magnetic resonance imaging: what is realistic? (2010) (28)
Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells. (1989) (28)
Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. (2000) (27)
Variants in CHEK 2 Other than 1100 delC Do Not Make a Major Contribution to Breast Cancer Susceptibility (2003) (27)
The dynamics of growth hormone and prolactin secretion in acromegalic patients with "mixed" pituitary tumours. (1979) (27)
Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: Preclinical and clinical studies (1990) (26)
Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy? (2007) (25)
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy (2004) (25)
Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma. (1989) (25)
THE DEFINITION OF TRUE RECURRENCE OF PITUITARY‐DEPENDENT CUSHING'S SYNDROME AFTER TRANSSPHENOIDAL OPERATION (1987) (25)
Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours. (1996) (24)
Differential Effects of Fibroblast Growth Factors on Expression of Genes of the Plasminogen Activator and Insulin-like Growth Factor Systems by Human Breast Fibroblasts (2002) (22)
The effect of tamoxifen on GH and PRL secretion by human pituitary tumors (1980) (22)
Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7). (1988) (21)
Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research. (1994) (21)
Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study) (2008) (21)
Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients (2005) (20)
The value of the thyrotropin-releasing hormone test in patients with prolactin-secreting pituitary tumors and suprasellar non-pituitary tumors. (1981) (20)
Genetic alterations in ovarian borderline tumours and ovarian carcinomas. (1999) (20)
Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse. (1999) (20)
The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine. (2008) (19)
Somatostatin receptors in differentiated ovarian tumors. (1991) (18)
European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. (1987) (18)
Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features (2001) (18)
Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients. (1994) (18)
Complete Sequencing of TP 53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer 1 (2000) (17)
Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer (1995) (17)
Prognostic and Predictive Value of p53 (1998) (17)
Efficacy of magnetic resonance imaging and mammography for breast cancer screening in women with a familial or genetic predisposition (2005) (17)
The Majority of 22 Dutch High-Risk Breast Cancer Families Are due to Either BRCA1 or BRCA2 (1996) (17)
LHRH-agonist treatment in metastatic prostate carcinoma. (1984) (16)
High prevalence of codon 213ARG→STOP mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands (1998) (16)
Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by luminometric immunoassay on 1491 tumor cytosols. (1997) (15)
Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines (2008) (15)
Direct antitumor effects of LH-RH analogs. (1992) (13)
A family history of breast cancer will not predict female early onset breast cancer in a population-based setting (2008) (13)
Prognostic and Predictive Factors and Targets for Therapy in Breast Cancer (2002) (13)
Manipulation of cell cycle kinetics: Influence on the cytotoxicity of doxorubicin in human breast cancer cells (1990) (12)
Association of rare MSH6 variants with familial breast cancer (2010) (12)
347 Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: Final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC) (1995) (12)
Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer. (2004) (12)
Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer. (1985) (12)
GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients (2007) (12)
Gene expression profiles and prognostic markers for primary breast cancer. (2007) (11)
An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer. (1996) (11)
Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome. (2005) (11)
Insulin-like growth factor 1 (IGF-1) and urokinase-type plasminogen activator (uPA) are inversely related in human breast fibroblasts (1999) (11)
Effects of sandostatin and castration on pancreatic carcinogenesis in rats and hamsters (1992) (11)
Value of estrogenic recruitment before chemotherapy: first randomized trial in primary breast cancer. (2000) (11)
Low-dose fortnightly methotrexate in advanced prostate cancer. The EORTC Genito-Urinary Tract Cancer Cooperative Group. (1990) (10)
Effects of castration, alone and in combination with aminoglutethimide, on growth of (pre)neoplastic lesions in exocrine pancreas of rats and hamsters. (1991) (10)
Sequential treatment of metastatic breast cancer with tamoxifen after megestrol acetate therapy and vice versa (a retrospective study) (1985) (10)
Breast Cancer Screening in High-Risk Women (1999) (9)
Prognostic Factors in Breast Cancer (1990) (8)
Effects of orchiectomy, alone or in combination with testosterone, and cyproterone acetate on exocrine pancreatic carcinogenesis in rats and hamsters (1992) (8)
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. (2005) (8)
Corrigendum: BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients (1997) (8)
Prognostic and Predictive Factors in Breast Cancer (1999) (7)
Chemotherapy with estrogenic recruitment in breast cancer: experimental and clinical studies. (1985) (7)
Prophylactic neuropeptide-analog treatment of a transplantable pancreatic tumor in rats (1987) (7)
TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative breast cancer (2006) (7)
Effects of somatostatin analog (SMS-A) treatment (sandostatin) in experimental and human cancer (1986) (7)
Second international symposium on 'Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents'. Meeting report, April 9-11, 1990, Rotterdam, The Netherlands. (1991) (7)
[Good results in periodic screening in women with increased risk of breast cancer; retrospective study]. (1995) (7)
Role of urokinase plasminogen activator in human breast cancer: Active involvement of stromal fibroblasts (1996) (6)
Vorozole (Rivizor™): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure (1998) (6)
MRI Screening for Breast Cancer in Women with a Familial or Genetic Predisposition (2005) (6)
THE FUNCTION OF THE PITUITARY‐THYROIDAL AXIS IN ACROMEGALIC PATIENTS V. PATIENTS WITH HYPERPROLACTINAEMIA AND A PITUITARY TUMOUR (1980) (6)
Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro. (1993) (6)
Survival of patients with breast cancer and BRCA1 mutations (1998) (6)
Cardiovascular mortality following breast cancer treatment (2004) (5)
Identi ® cation and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in ® rst-line chemotherapy in advanced breast cancer (2000) (5)
Orchidectomy and oestrogens as secondary forms of treatment for metastatic prostatic cancer. (1985) (5)
Gene screening and prevention of hereditary breast cancer: A clinical view (2003) (5)
Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: Preliminary results of a double-blind randomized study of the eortic breast cancer cooperative group (1990) (5)
286 An analogue of LHRH antagonizes the growth-stimulating effect of oestradiol on human breast cancer cells in culture (MCF-7) (1983) (5)
Direct effects of LHRH analogs on tumor cells (1986) (5)
Epigenetic signature predicts failure of endocrine therapy in patients with recurrent breast cancer (2003) (4)
Loss of imprinting of IGF 2 and not H 19 in breast cancer , adjacent normal tissue and derived ¢ broblast cultures (1998) (4)
Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer (2005) (4)
Relationship of p53, uPA, pS2, EGF-R, and c-ERBB2, with response to systemic treatment in recurrent breast cancer patient (1997) (4)
Direct Antitumor Effects of an LH-RH Agonist (1988) (4)
260 Treatment of advanced breastcancer with tamoxifen after megestrol acetate therapy and vice versa, a retrospective study (1983) (4)
Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer (1992) (4)
Chemotherapy with estrogenic recruitment in breast cancer : Experimental background and clinical studies conducted by the EORTC breast cancer cooperative group (1986) (4)
PP-8-1 Combined estroyen suppression and receptor (ER) blockade by buserelin (LHRH-A) and tamoxifen (TAM) in premenopausal metastatic breast cancer: Preliminary results of a 3-arm randomized study (EORTC 10881) (1996) (4)
Phase II study on oral N-methylformamide in metastatic colorectal cancer. (1987) (3)
Effects of sandostatin, alone and in combination with surgical castration, on pancreatic carcinogenesis in rats and hamsters (1996) (3)
Prophylactic surgery in BRCA1/2 mutation carriers Predictive factors and follow-up (1999) (3)
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group). (1998) (3)
CYP2C19 genotype predicts duration of response to tamoxifen in advanced breast cancer (2005) (3)
Differences in secretion characteristics in Cushing’s disease with and without radiologically evident pituitary tumors (1980) (3)
Hormonal manipulation of cancer : peptides, growth factors and new (anti) stroidal agents : abstracts, Rotterdam, The Netherlands, 9,10-11 April 1990 (1990) (3)
Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro (1998) (3)
Comparison of enzyme immunoassay and dextran-coated charcoal techniques for progesterone receptor determination in human breast cancer cytosols. (1988) (3)
Factors affecting sensitivity and specificity of screening mammography and MRI in women with a hereditary risk for breast cancer (2006) (3)
Effects of aminoglutethimide, alone and in combination with surgical castration, on pancreatic carcinogenesis in rats and hamsters (1995) (3)
EORTC 10941: A phase II study of liarozole in postmenopausal patients with ‘Chemotherapy-Resistant’ or ‘Potentially Hormone Sensitive’ metastatic breast cancer (2000) (3)
The psychological impact of regular surveillance in women at increased risk for hereditary breast cancer (2005) (3)
Other Endocrine and Biological Agents in the Treatment of Advanced Breast Cancer (2002) (3)
Antiprogestational Treatment of Breast Cancer: Preclinical and Clinical Experience with Different Antiprogestins (1994) (2)
Endocrine, Pharmacokinetic and Clinical Effects of LHRH Analogue Treatment in Patients with Malignant and Benign Breast Disease (1990) (2)
Screening women with a family history of breast cancer (1999) (2)
The treatment of acromegaly. (1979) (2)
Comment on Screening by MRI Mentioned in the Reviews by Narod and Møller (2004) (2)
Genetic testing and prophylactic surgery in familiar clusters of BRCA1 or BRCA2 mutation (2000) (2)
EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): 5 years of European collaboration in new drug development for breast cancer. (1997) (2)
Phase II study of the eortc breast group with vorozole (R 83842), a new non-steroidal aromatase inhibitor in metastatic breast cancer (MBC) — preliminary results (1993) (2)
The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors (1990) (2)
Endocrine effects of LHRH-agonist (buserelin) implants and of combined treatment of high dose buserelin S.C. with tamoxifen in premenopausal women (1987) (1)
Diagnosis and treatment of pituitary tumours: a starting-point for manipulation of cancer with hypothalamic hormones (1987) (1)
Herceptin in single and combined treatment modalities in pretreated patients with metastatic breast cancer: the Dutch experience (2002) (1)
Long-term LHRH-agonist treatment for metastatic bbeast cancer in single and combined drug regimens (1984) (1)
Prophylactic mastectomy in high risk women (2004) (1)
Screening women with a familial or genetic predisposition to breast cancer: costs and effects of alternative screening policies (2006) (1)
The efficacy of endocrine combination therapy with aminoglutethimide and hydrocortisone in metastatic prostatic cancer refractory to standard endocrine therapies (2001) (1)
Manipulation of cell cycle kinetics; influence on uptake, cellular distribution and cytotoxicity of doxorubicin☆ (1990) (1)
Session 19. Steroids and cancerEffects on mammary tumor growth, receptor contents and organ weights by chronic treatment with the antiprogestin mefiprestone (MFP, RU486) in comparison with the progestin megestrol acetate (MA) in the rat (1986) (1)
Cosmetic outcome of prophylactic mastectomy followed by immediate breast reconstruction using a subpectorally placed silicone prosthesis in women at risk of hereditary breast cancer or with a proven BRCA1 or BRCA2 germ-line mutation (2004) (1)
BRCA1- versus non-BRCA1/2-associated breast cancer (BC): Tumor characteristics and impact of prognostic and treatment factors (2004) (1)
PP-8-6 Paclitaxel (P) versus doxorublcin (D) as first line chemotherapy (CT) in advanced breast cancer (ABC): A randomized trial with crossover of the EORTC-IDBBC in collaboration with EORTC-ECSG (1996) (1)
Gene expression profile associated with breast cancer metastasizing to bone (2006) (1)
Prophylactic mastectomy prevents contralateral breast cancer , without positive impact on survival in BRCA mutation carriers with a previous history of unilateral breast cancer (2003) (1)
Modulation of development of dietary fat-promoted (pre)neoplastic pancreatic lesions in bop-treated hamsters by (anti) hormones (1990) (1)
Prediction of cancer outcome with microarrays (2005) (1)
Treatment of patients (PTS) with metastatic pancreatic and gastrointestinal tumors with a somatostatin analog (sandostatin): A phase II study including endocrine effects (1987) (1)
436 A Retrospective study op 429 patients with a thyroidal tumour (1983) (1)
Uterine radiation dose from open sources: the potential for underestimation (2004) (1)
Suramin: Pharmacokinetic monitoring, haematological and antitumor effects on rats bearing transplantable pancreatic tumors (1990) (1)
Treatment of metastatic thyroid carcinoma with I131 (1987) (1)
CHEK 2 1100 delC Is a SusceptibilityAllele for HNPCC-Related Colorectal (2008) (1)
Growth-inhibitory effects of somatostatin (analogs) on human breast cancer cells in vitro (1987) (1)
PP-9-4 The predictive value of the urokinase system of plasminogen activation in recurrent breast cancer (1996) (0)
22 Total tumour tissue levels of tissue inhibitor of metalloproteinases-1 as a prognostic marker in breast cancer: an EORTC validation study of 2984 patients (2003) (0)
Epidermal growth factor receptor (EGF-R) in advanced ovarian carcinoma; lack of correlation between immunohistochemistry and biochemistry (1990) (0)
The significance of prostate specific antigen (PSA) in breast cancer (1998) (0)
Age-specific tumour features, contralateral breast cancer (CBC) risk and survival in BRCA1-associated breast cancer (2006) (0)
Screening for Breast Cancer in Women with a Familial or Genetic Predisposition: Magnetic Resonance Imaging versus Mammography (2008) (0)
The relationship of growth factor (EGF, IGF-1) content and EGF-receptor levels with the amount of steroid receptors (ER, PgR) in human breast tumors (1987) (0)
95. Absence of seasonal variation in the content of oestrogen and progesterone receptors of human primary mammary tumours (1982) (0)
23 Differential susceptibility of primary human breast fibroblasts to TGFβ1 coincides with the proneness of these (myo)fibroblasts to produce uPA in response to factor(s) released by human epithelial carcinoma cells in vitro (1997) (0)
PS2 helps to predict responders to tamoxifen therapy in patients with recurrent breast cancer (1998) (0)
Effect of estradiol (E2) on cell cycle distribution of MCF-7 Human breast cancer cells: Analysis by flow cytometry (PI) and immunocytochemistry (Ki-67) (1987) (0)
Measurement of progesterone receptors in human breast cancer by monoclonal enzyme immunoassay (1987) (0)
Antitumor effects of endocrine treatment of mammary tumor bearing rats with combinations of the antiprogestin mifepristone (RU486) and LHRH-analogs (buserelin or zoladex) or tamoxifen (1987) (0)
Evaluation of biological prognostic factors in relation to local recurrence after breast conserving therapy (1998) (0)
SY-7-3 Growth factor receptors (1996) (0)
Long-term registration of prophylactic mastectomy (PM) in BRCA1/2 mutation carriers and women at increased breast cancer (BC) risk due to a family history at a single institution (2006) (0)
Effects of sandostatin, alone and in combination with surgical castration, on pancreatic carcinogenesis in rats and hamsters. (1996) (0)
Angiogenesis and efficacy of endocrine and chemotherapy in recurrent breast cancer (2000) (0)
DNA damage control genes that predispose for radiation-induced breast cancer (2004) (0)
Magnetic resonance imaging was more sensitive than mammography for detecting breast cancer in high-risk women (2005) (0)
Survival in BRCA1-associated breast cancer: long-term follow-up and prognostic factors (2004) (0)
[Chemotherapy in metastasized breast carcinoma]. (1998) (0)
EORTC 10941; Final results of a phase II study of liarozole fumarate in patients with metastatic breast cancer (1998) (0)
Increased risk of tumor recurrence following breast conserving therapy (BCT) in hereditary breast cancer as compared with sporadic breast cancer (BC) (1998) (0)
EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): Seven years of active European collaboration (1998) (0)
Presymptomatic testing for hereditary breast/ovarian cancer (HBOC): Is there psychological distress in the pre-test period? (1998) (0)
440 Combination of LHRH-analogde and megesteol acetate (MA) in breast cancer (1983) (0)
Prognostic factors and impact of contralateral cancer on survival of hereditary breast cancer (2006) (0)
Endocrine effects of Aminoglutethimide (Ag) plus Hydrocortisone (HC) versus high dose of hydrocortisone in postmenopausal breast cancer (1986) (0)
Identification of tumor-associated factors responsible for regulating uPA production by breast cancer fibroblasts. (1999) (0)
Endocrine changes during treatment of prostate carcinoma (PCA) patients with the LHRH-agonist buserelin (HOE 766) (1986) (0)
New Diagnostic Methods and Treatment Modalities in Breast Cancer (1992) (0)
2002 ORAL Low SIAH2 expression in breast cancer is associated with resistance to endocrine therapy (2007) (0)
Hormonal treatment of rat pancreatic tumors with aminoglutethimide (AG), surgical castration and somatostatin analogs (1987) (0)
Ki-67 STAINING IN BENIGN , BORDERLINE , MALIGNANT PRIMARY AND METASTATIC OVARIAN TUMORS : CORRELATION RECEPTOR AND CATHEPSIN D WITH STEROID RECEPTORS , EPIDERMAL-GROWTH-FACTOR (2006) (0)
Tissue inhibitor of metalloproteinases-1 (TIMP-1) and prognosis in primary breast cancer: an EORTC—RBG collaborative validation study including 2984 patients (2004) (0)
Prevalent and incident rounds in a breast cancer screening program with mammography and MRI for high risk women (2004) (0)
652 The relation of extensive intraductal carcinoma component (EIC) with prognosis and treatment results of patients (PTS) with primary breast cancer (1995) (0)
Use o f G enetic T esting a nd P rophylactic M astectomy a nd Oophorectomy i n W omen W ith B reast o r O varian C ancer F rom Families W ith a BRCA1 or BRCA2 Mutation (2003) (0)
Mutations in the BRCA1 and BRCA2 genes: Uptake of presymptomatic DMA test, preventive choices and breast cancer risk after prophylactic mastectomy (1998) (0)
Tumour endocrinology, genetics, prognostic factors and experimental therapy of cancer (1998) (0)
PP-1-7 Accumulation of TP53 as predictor of response to chemotherapy of recurrent breast cancer (1996) (0)
Patients with Recurrent Breast Cancer Aminotransferase with Response to Endocrine Therapy in Association of DNA Methylation of Phosphoserine (2005) (0)
PP-6-2 Incidence and prognostic value of routine clinical parameters in 2273 patients with primary breast cancer treated between 1978–1990 (1996) (0)
Combination of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) has not only prognostic but also predictive impact in primary breast cancer (2003) (0)
Combination of antimetastatic and antiproliferative therapies in the treatment of experimental breast cancer (1998) (0)
Long-term treatment with the LHRH-agonist buserelin in metastatic prostatic cancer (1986) (0)
E21. What is the best therapy for ER-positive breast cancer? (2004) (0)
Poster presentationsPP-4-40 Histologic findings in prophylactic mastectomy specimens from women with hereditary risk factors (1996) (0)
903 ORAL Long-term risk of contralateral breast cancer in relation to treatment (2007) (0)
Response to first line chemotherapy in BRCA1 and BRCA2 mutation carriers with metastatic breast cancer (MBC) (2008) (0)
Survival in breast cancer associated with germline mutations of BRCA1 (1997) (0)
Progress in Clinical and Biological Research, Volume 269: EORTC Genitourinary Group Monograph 5 (1989) (0)
Contralateral breast cancer and survival in non-BRCA1/2 hereditary breast cancer: a case control study (2004) (0)
The relationship of patient characteristics, estrogen (ER) and progestin receptor (PR), and site of relapse in breast cancer: a multivariate analysis (1987) (0)
Longterm psychological riskprofiles in women at risk for hereditary breast cancer adhering to surveillance or opting for prophylactic mastectomy (2008) (0)
PP-7-15 Org-OD14 significantly inhibits DMBA induced mammary tumor growth in rats: Effects of combination therapy with tamoxifen or the antiprogestin org-31710 (1996) (0)
LH receptor variance (2009) (0)
Breast cancer extracellular matrix gene cluster: Association with prognosis and response to tamoxifen. (2007) (0)
The contribution of ATM germline mutations to radiation-induced breast cancer (2000) (0)
Downregulated expression of SIAH2 is associated with resistance to endocrine therapy in breast cancer (2007) (0)
Expression of the HOXB13-to-IL 17BR-gene ratio in oestrogen receptor positive primary breast carcinomas: Relation with tumour aggressiveness and response to tamoxifen (2006) (0)
Hormonal manipulation of MCF-7 breast cancer cells: Implications for chemotherapy (1986) (0)
Low expression levels of SIAH2 are associated with resistance to endocrine therapy in breast cancer (2008) (0)
Transforming growth factor beta secretion by human breast fibroblasts in vitro (1993) (0)
Four human breast cancer cell lines with biallelic inactivating gene mutations (2020) (0)
TRH test for prolactinoma. (1979) (0)
PP-7-1 phase II study of liarozole in advanced breast cancer patients (1996) (0)
Association of rare variants with familial breast cancer (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jan G. M. Klijn?

Jan G. M. Klijn is affiliated with the following schools:

Pomeranian Medical University in Szczecin